Impact of Hemodialysis and Post-Dialysis Period on Granular Activity Levels

John W Larkin (✉ john.larkin@fmc-na.com)

Fresenius Medical Care North America <https://orcid.org/0000-0001-8873-8971>

Maggie Han

Renal Research Institute

Hao Han

Fresenius Medical Care AG & Co. KGaA

Murilo H Guedes

Pontificia Universidade Catolica do Parana

Priscila Bezerra Gonçalves

Pontificia Universidade Catolica do Parana

Carlos Eduardo Poli-de-Figueiredo

Pontificia Universidade Catolica do Rio Grande do Sul

Américo Lourenço Cuvello-Neto

Hospital Alemão Oswaldo Cruz

Ana Beatriz L Barra

Fresenius Medical Care Brazil

Thyago Proença de Moraes

Pontificia Universidade Catolica do Parana

Len A Usvyat

Fresenius Medical Care AG & Co. KGaA

Peter Kotanko

Renal Research Institute

Maria Eugenia F Canziani

Universidade Federal de Sao Paulo

Jochen G Raimann

Renal Research Institute

Roberto Pecoits-Filho

Pontificia Universidade Catolica do Parana

Research article

Keywords: High-Flux Hemodialysis, Physical Activity, Steps, Moderate-to-Vigorous Activity, Accelerometry, End Stage Kidney Disease

Posted Date: October 24th, 2019

DOI: <https://doi.org/10.21203/rs.2.16392/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.
[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Nephrology on May 25th, 2020. See the published version at <https://doi.org/10.1186/s12882-020-01853-2>.

Abstract

Background: Physical activity (PA) is typically lower on hemodialysis (HD) days. Albeit intradialytic inactivity is expected, it is unknown whether recovery after HD contributes to low PA. We investigated the impact of HD and post-HD period on granular PA relative to HD timing.

Methods: We used baseline data from the HDFIT trial conducted from August 2016 to October 2017. Accelerometry measured PA over one week in patients who received thrice-weekly high-flux HD (vintage 3 to 24 months), were clinically stable, and had no ambulatory limitations. PA was assessed on HD days (0 to ≤ 24 hours after start HD), first non-HD days (0 to ≤ 24 hours after start HD) and second non-HD day (>24 to ≤ 48 hours after start HD). PA was recorded in blocks/slices: 4 hours during HD, 0 to ≤ 2 hours post-HD (30 minute slices), and >2 to ≤ 20 hours post-HD (4.5 hour slices). Blocks/slices of PA were captured at concurrent/parallel times on first/second non-HD days compared to HD days.

Results: Among 195 patients (mean age 53 ± 15 years, 71% male), step counts per 24-hours were 3919 ± 2899 on HD days, 5308 ± 3131 on first non-HD days ($p < 0.001$), and 4926 ± 3413 on second non-HD days ($p = 0.032$). During concurrent/parallel times to HD on first and second non-HD days, patients took 1308 and 1128 more steps (both $p < 0.001$). Patients took 276 more steps and had highest rates of steps/hour 2-hours post-HD versus same times on first non-HD days (all $p < 0.05$). Consistent findings were observed on second non-HD days.

Conclusions: PA was higher within 2-hours of HD versus same times on non-HD days. Lower PA on HD days was attributable to intradialytic inactivity. The established PA profiles are of importance to the design and development of exercise programs that aim to increase activity during and between HD treatments. Trial Registration: HDFIT was registered 20 April 2016 on ClinicalTrials.gov (NCT02787161) <https://clinicaltrials.gov/ct2/show/NCT02787161>.

Background

A physically active lifestyle can improve and maintain health in children, adults, and populations with disabilities or chronic diseases.[1–4] People with end stage kidney disease (ESKD) typically perform low levels of physical activity (PA) (e.g. $< 5,000$ steps/day), placing them at higher risk for obesity, diminished quality of life, cardiovascular diseases, and mortality.[3–8] Inactivity in ESKD is likely influenced by high prevalence of physical disabilities and comorbidities, and social, environmental, and patient characteristics.[3, 4, 9–15] Albeit lifesaving, dialysis can be associated with symptoms such as nausea, body aches, and fatigue impacting PA.[12, 16, 17] Understanding profiles and drivers of PA in ESKD is important to find optimal treatment options and design interventions.

Profiles of objectively measured PA are loosely defined in ESKD. Studies in hemodialysis (HD) populations using pedometers/accelerometers report average PA levels range from 2,446 to 8,454 steps/day; PA is lower on HD days versus non-HD days.[6, 7, 18–25] and PA decreases with longer vintage.[18, 24] A limitation of studies conducted to date is they assessed PA by calendar days (i.e. 0:00–

23:59 hours) and have not assessed PA relative to the timing of HD.[2, 5–7, 18–27] It is unknown if recovery after HD may influence PA on HD days in addition to requirements of sitting/lying during HD. With the potential impacts of HD on PA, granular assessments are needed to find timepoints for risk assessment and interventions.

PA was measured via accelerometry in HD patients during the baseline period of the HDFIT randomized controlled trial (RCT).[28, 29] Various types of PA were assessed in 24-hour periods relative to the start of HD (0-to-≤24 hours after start HD) and concurrent/parallel periods to HD days on the subsequent first and second non-HD days (>24-to-≤48 and >48-to-≤72 hours after start HD, respectively). PA data was captured in granular slices. Our primary hypothesis was granular slices of PA would be lower on HD days, particularly immediately after HD, versus concurrent time segments on the first and second non-HD days.

Methods

Trial design:

HDFIT was a prospective, multi-center, unblinded, RCT studying the impact of modality on objective PA. [28] The HDFIT protocol and trial design has been previously published.[29] After a run-in baseline period up to 4 weeks, eligible participants were randomized in a 1:1 ratio to high-volume online hemodiafiltration (HDF) or high-flux HD for a 6-month interventional period and 12-month observational follow-up. This ancillary study investigated PA profiles during the run-in baseline period ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02787161) Identifier: NCT02787161; registration date 20 April 2016).

Setting and Participants:

Fourteen dialysis centers in Brazil were activated for recruitment. The Center for Epidemiology and Clinical Research (EPICENTER) academic clinical research organization (ACRO) based at Pontifícia Universidade Católica do Paraná (PUCPR) managed the trial.

Patients provided written informed consent before study activities. Trial included adults (age ≥ 18 years) who initiated renal replacement therapy between 3 and 24 months prior to randomization, were treated with thrice-weekly HD, used a fistula/graft or permanent catheter, had previous Kt/V ≥ 1.2 , and were considered clinically stable. Patients with severely limited mobility/ambulation, poor treatment adherence, or a life expectancy of <3 months because of non-renal comorbidities were excluded.

Ethical Considerations:

The protocol, consent form, and study documents were approved PUCPR ethics review board (central application# 54926916.7.1001.0020; approval# 1.538.784). Trial was conducted in accordance with the Declaration of Helsinki.

Procedures and Interventions:

PA was continuously measured over 7 days using a validated waist worn tri-axial accelerometer (ActiGraph™ wGT3X-BT model, Pensacola, USA).[19, 30–33] Patients were instructed to remove the accelerometer during sleep and bathing, and record their HD, sleep, and bathing times during monitoring.

Patient demographics (age, sex, race), clinical, laboratory, and social parameters were recorded from medical records and/or assessments. Clinical characteristics applicable to this ancillary study included etiology of ESKD, comorbidities, access type, height, pre-HD/post-HD/estimated dry weight, pre-HD/post-HD systolic and diastolic blood pressure (SBP/DBP), pulse, and HD parameters. Educational level, family income, employment status, transportation method to clinic, and distance from clinic to the patient's residence was also captured.

Recent monthly values for pre-/post-HD blood urea nitrogen (BUN) and hemoglobin, and quarterly values for albumin, potassium, calcium, phosphate, intact parathyroid hormone (iPTH) were captured from the medical records. HD adequacy (single-pool Kt/V) was calculated from BUN.[34]

Endpoints:

Primary endpoints were the difference in steps and moderate-to-vigorous PA (MVPA)/24 hours and between prespecified periods after dialysis on HD days versus concurrent/parallel periods at the same time on subsequent first or second non-HD days; similar assessments were performed for light PA, sedentary time, and metabolic rate (MET) levels. Secondary endpoints were the difference in steps and MVPA/24 hours and in prespecified periods after the start of dialysis: i) on the first versus second or third HD session of the week, and ii) HD start before versus after 1500 hours.

Statistical Methods:

Physical Activity Analysis:

Raw accelerometer data were uncompressed using ActiLife v6.13.3 software (ActiGraph LLC, Pensacola, USA) and bandpass filtered using default filter with a 60 second epoch length. Data validation and filtering of non-wear time measurements was performed via vector magnitude and Choi 2011 algorithm.[35] We used a 60-minute window for consecutive zeros/non-zeros.[36]

PA data was cleaned, sliced, computed and exported using a custom coded file denoting slices based off start and end time of each HD session. Freedson VM3 Combination (2011) algorithm was used to calculate energy expenditure.[37] Raw acceleration cut points were: Sedentary = 0–99 counts/minute (CPM); Light = 100–2689 CPM; Moderate = 2690–6166 CPM; Vigorous = 6167–9642 CPM; Very Vigorous

= 9643-infinity CPM.[37] Freedson Adult 1998 algorithm was used to calculate MET levels.[38] MET levels represent the amount of energy expended per unit time in reference to sitting/resting MET level of 1. If monitor was worn during sleep, custom export files were coded to exclude the data using patient-reported sleep times.

Extraction of 24-hour periods of PA data was performed in 3 blocks consisting of 9 slices: Block A) HD/concurrent non-HD period with 1 slice of PA data, Block B) ≤ 2 -hour post-HD/concurrent non-HD period with four data slices of 30 minutes each, and Block C) >2 -to- ≤ 20 -hour post-HD/concurrent non-HD period with four data slices of 4.5 hours each (*Figure 1*).

Analysis of Endpoints:

Primary endpoints were analyzed by ANOVA and pooled two-way t-tests. Granular PA data for steps and minutes of MVPA was normalized to a rate per hour metric for visualization of data in prespecified periods. Secondary endpoints (i) and (ii) were compared using paired and unpaired t-tests, respectively.

Results

Patient Characteristics:

HDFIT enrolled 195 patients from 13 of 14 sites throughout Brazil during August 2016 to October 2017 (*Figure 2*). On average, patients were 53 years old, 71% male, 59% white race, 35% had diabetes, 17% had coronary artery disease, 8% had congestive heart failure; 89% used an arteriovenous fistula/graft and 55% had ESKD attributable to diabetes/hypertension. Family income was 2-to-10 times the Brazilian minimum wage in 73% and below that range in 18%. Fifty-six percent completed high school or higher. Seventy-two percent resided ≥ 7 kilometers from the dialysis clinic; 43% drove by car and 33% by public transportation to the HD clinic. Mean albumin was 4.0 ± 0.4 g/dL, phosphate 5.3 ± 1.4 mg/dL, iPTH 350.5 ± 290.0 pg/mL, hemoglobin 11.1 ± 1.6 g/dL, and Kt/V 1.5 ± 0.4 (*Table 1*).

Profiles of Physical Activity:

Among 195 HD patients with PA monitored, 176 had valid data. On average, patients took 4654 ± 3468 steps, their energy expenditure rate was 1.1 ± 0.2 MET (kcal/kg/hr), and they performed 23.9 ± 32.6 minutes of MVPA, 361.2 ± 134.5 minutes of light PA, and 488.0 ± 148.0 minutes of sedentary time per 24-hour period (*Table 2*). ANOVA of PA on HD days and the first, and second non-HD days revealed differences between groups for steps ($p < 0.001$), MET ($p = 0.043$), MVPA ($p < 0.001$), light PA ($p < 0.0001$) and sedentary time ($p < 0.001$) per 24 hours.

On the first non-HD days, patients performed 1389 more steps ($p = 0.032$), 7.2 more minutes of MVPA ($p = 0.021$), 107.9 more minutes of light PA ($p < 0.0001$), and 69.8 fewer minutes of sedentary time

($p < 0.0001$) per 24-hours compared to HD days. MET levels were the same on the first non-HD days versus HD days (*Table 2*).

On the second non-HD day, patients performed 1007 more steps ($p < 0.001$), 0.02 lower MET ($p = 0.027$), 92.2 more minutes of light PA ($p < 0.0001$), and 35.8 fewer minutes of sedentary time ($p = 0.026$) per 24-hours compared to HD days. Minutes of MVPA were similar for the second non-HD day versus HD days (*Table 2*).

Granular Profiles of Physical Activity:

Assessment of granular PA levels revealed, as expected, that sitting/lying during HD was associated with the most remarkable differences on HD days versus concurrent/parallel times on non-HD days. There were small increases in PA during the 2-hour post-HD period versus the same times on non-HD days (*Table 3*).

At concurrent times to HD on the subsequent first non-HD day, patients performed an average of 1,308 more steps ($p < 0.001$), 0.1 higher MET ($p < 0.001$), 7.2 more minutes of MVPA ($p < 0.001$), 88.1 more minutes of light PA ($p < 0.001$), and 79.2 fewer minutes of sedentary time; on the second non-HD day patients performed 1,128 more steps ($p < 0.001$), 0.1 higher MET ($p < 0.001$), 5.5 more minutes of MVPA ($p < 0.001$), 82.4 more minutes of light PA ($p < 0.001$), and 64.8 fewer minutes of sedentary time compared to HD days (*Table 3*). During HD patients exhibited MET levels indicative of sitting still/resting (MET = 1.0) and had 178.0 minutes of sedentary time, however they did perform low levels of some types of PA (97 steps, 0.3 minutes of MVPA, 13.3 minutes of light PA) that are likely attributable to slight movements during HD and could also be due to discrepancies in self-reported dialysis times captured from patient diaries.

Patients performed slightly more PA during the 2-hour post-HD period on HD days versus concurrent times on subsequent non-HD days. During the 0-to-30, 31-to-60, and 61-to-90-minute post-HD slices on HD days, patients tended to take more steps, perform more MVPA/light PA, and spend less time in a sedentary state compared to concurrent times on both the first and second non-HD days. During the 91-to-120-minute slice on HD days, patients tended to perform slightly more steps than concurrent times on the first non-HD days (*Table 3*). There was a small signal for patients performing lower PA during the >2-to-≤6.5-hour post-HD period on HD days versus the first non-HD days, where patients performed 13.9 fewer minutes of light PA ($p = 0.009$).

Rates of Granular Physical Activity:

Normalized rates of steps and minutes of MVPA performed per hour were calculated to visualize relative distinctions in prespecified periods (*Figures 3 and 4*). Compared to the treatment time on HD days,

patients performed rates of 327 and 282 more steps/hour and 1.8 and 1.4 more minutes of MVPA/hour during the concurrent times on the subsequent first and second non-HD days respectively (all $p < 0.001$).

Patients generally performed higher rates of steps and minutes of MVPA in the 2-hour post-HD period on HD days (*Figures 3 and 4*). In the 0-to–30-minute post-HD period on HD days, patients performed rates of 161 and 248 more steps/hour compared to the first and second non-HD days respectively (both $p < 0.01$); patients performed 1.4 more minutes of MVPA/hour on HD days versus the second-non-HD day ($p < 0.01$). During the 31-to–60, 61-to–90, and 91-to–120-minute slices of PA following HD, patients performed significantly more steps than concurrent times on both the first and second non-HD day (*Figure 3*).

Profiles of Physical Activity by Dialysis Shift and Day of the Week:

Patients with HD sessions starting before 1500 hours (first and second HD shift) performed 2157 fewer steps ($p < 0.0001$) and 18.6 fewer minutes of MVPA ($p < 0.0001$) per 24-hours on HD days versus patients with HD sessions starting after 1500 hours (third HD shift) (*Table 4*).

Granular assessment of PA identified patients with HD starting before 1500 hours performed 116, 1741, and 871 fewer steps during the 0-to–30-minute, >11.0-to–≤15.5-hour, and >15.5-to–≤20.0-hour post-HD periods on HD days respectively versus patients with HD starting after 1500 hours (all $p < 0.05$). Despite this, patients with HD starting before 1500 hours performed 68 and 680 more steps during the 91-to–120-minute and >2.0-to–≤6.5-hour post-HD periods versus patients with HD starting after 1500 hours (both $p < 0.05$). Similar patterns of PA were observed for MVPA (*Table 5*).

PA levels on HD days were similar on the first (Monday/Tuesday), second (Wednesday/Thursday) or third (Friday/Saturday) HD session of the week and did not differ between groups in ANOVA and t-test comparisons (*Table 6*).

Granular steps did not differ by day of the week. Patients performed 0.4 more minutes of MVPA during the 91-to–120-minute post-HD period on the first versus the third HD session of the week ($p = 0.042$); no other differences were observed (*Table 7*).

Discussion

This analysis of baseline data from the HDFIT trial characterized the profiles of PA in reference to the timing of HD and revealed unique PA patterns in the post-HD period, compared to concurrent times on subsequent non-HD days. Clinically stable prevalent HD patients in the first 2 years of HD who did not have limitations in ambulation tended to be highly sedentary, with levels of PA that only increased their metabolic energy expenditure rate by one tenth of a kcal/kg/hour above the resting level. As anticipated, PA levels per 24 hours were lower on HD days compared to the first and second non-HD days. PA levels and patterns per 24 hours are consistent with other literature reports of PA measured on calendar days

(i.e. 0:00–23:59 hours).[7, 18–25] Novel accelerometry methods allowed us to characterize PA relative to the time of the start of HD. Lower PA levels on HD days were found to be primarily attributable to inactivity during HD. While this finding is not surprising, it has neither been documented nor quantified previously. Inactivity during HD accounts for >1000 fewer steps on HD days. Contrary to our main hypothesis, patients had higher levels and the highest rates of PA within 2 hours after HD as compared to concurrent times on subsequent non-HD days, yet this only accounted for about 300 additional steps. PA profiles differed in later HD shifts, with HD starting after 1500 hours being associated with patients taking >2000 more steps 24 hours after HD. These distinct levels were driven by activity performed within 30 minutes after HD and 11-to–20 hours after HD. The findings might be representative of late shift patients being a more functional subgroup who perform more daily activities.

The literature reports relatively sedentary levels of PA in the HD population (<5,000 steps/day, <21.5 minutes of MVPA/day, <3.0 MET (kcal/kg/hour) or equivalent measures), however, large variations exist (differences up to 6000+ steps/day) depending on populations and geographies.[1, 2, 6, 7, 18–25, 39] Our findings are consistent with HD patients generally performing <4000 steps/24-hour period on HD days, and about 5000 steps/24-hour period on non-HD days. Despite this, patients achieved goals for MVPA on non-HD days in line with WHO recommendations of ≥ 150 minutes of MVPA/week.[39] However, MET levels were only 0.1 kcal/kg/hour above the resting level.

Contrary to our expectation, PA was higher following HD. Increased post-HD PA is might be associated with transportation from the clinic, especially in the first hour when steps and rates are the highest. Notably, 33% of patients used public transportation use to attend HD. Other contributing factors may be improved fluid and electrolyte status after HD, and routine activities performed after HD (i.e. cooking, shopping, errands), which may associate to increased levels of light PA observed 31-to–90 minutes after HD. The finding that PA rates are the highest in the first hours after HD might be signaling an important timepoint in the post-HD period that warrants investigation in the future. It has been recognized sudden death typically occurs within 12 hours of HD.[40] However, it is unknown if higher PA rates could cause hemodynamic stress immediately following HD, which itself inherently causes a hemodynamic challenge.[41] HD schedules before/after 1500 hours might also influence PA on HD days, but our findings could be related to sleep patterns and patient characteristics, and a selection bias may be contributing to the findings. Nonetheless, being treated on the first HD shift has been previously found to be associated to altered sleep patterns.[6, 7] The HD day of the week did not remarkably affect PA.

PA is of utmost importance to improving/maintaining health in all populations, and it is a useful surrogate marker of negative outcomes. The United States guidelines for PA suggest performing any higher quantity of PA yields some health benefits.[42] Select European and Oceania countries have adopted the concept that exercise is “medicine” for dialysis patients and should be prescribed, but unfortunately, this philosophy has not been adopted in many countries in the world.[43] General and elderly populations have been shown to exhibit an inverse relationship between steps taken and outcomes.[44–48] Achievement of increases of 1000 more steps per day associates with about a 5% lower cardiovascular event rate and a 15% lower all-cause mortality rate.[44, 45] A 7-year observational

study in HD patients indicated taking ≥ 5000 steps a day improves the cumulative survival rate by 18.5 percentage points compared to having < 5000 steps daily.[24] In addition, patients who had a 30% decrease in daily steps had a 3-fold higher adjusted risk of death compared to patients with a 30% increase.[24]

Intradialytic exercise programs could potentially increase PA profiles on HD days. Despite that we established patients perform the highest levels and rates of activity within 2 hours of HD, the requirements of sitting/lying during the HD treatment was found to be the primary cause of higher inactivity on HD days. Clinicians, care teams and the nephrology community should recognize HD regimens are a major factor negatively impacting activity levels. A RCT has shown 4 months of intradialytic pedaling exercise decreased arterial stiffness.[49] Although intradialytic exercise may be a low hanging fruit for targeting interventions, with a higher potential to yield beneficial health outcomes, it can only reach patients 12 hours per week. Developing both intradialytic and interdialytic exercise programs should be a high priority for providers and clinicians as a means to increase PA in this largely sedentary population. We believe it will be of importance for clinicians to prescribe exercise as a medicine in a patient centric manner and routinely track adherence. Programs can be simple and not require additional resources, such as prescribing a 20 minute walk every day and leg lifts/stretching/Pilates during each HD treatment.

While our study has many strengths including use of high-quality RCT data, there are some limitations. Patients may not be representative of the overall HD population, but specifically generalizable to patients in the first two years of HD without impaired mobility/ambulation who are adherent with HD. We used self-reported HD times which may be inaccurate. There is also a potential for undercounting of PA using ActiLife software default algorithm, which has been validated in younger people performing exercise.[37, 38] Nonetheless, accelerometry is internally consistent and PA levels were found to be similar with previous reports.[7, 18–25] Rates of PA were calculated by period without adjustment for sleep time, which was excluded per protocol. Although this does not influence absolute values of PA, it could affect normalized rates.

Conclusion

In conclusion, the findings identify patients performed higher PA levels and the highest PA rates in the 2-hour post-HD period on HD days compared to concurrent times on non-HD days, however, the requirement of sitting/lying during HD causes overall 24-hour PA levels on HD days to be lower than non-HD days. Timing of the HD session may associate to distinct PA levels, but further investigations are needed. Exercise programs should be developed that increase activity during and between HD treatments.

Abbreviations

ACRO: Academic clinical research organization

ANOVA: Analysis of variance

BUN: Blood urea nitrogen

CKD: Chronic kidney disease

CPM: Counts per minute

DBP: Diastolic blood pressure

EPICENTER: Center for Epidemiology and Clinical Research

ESKD: end stage kidney disease

HD: Hemodialysis

HDF: Hemodiafiltration

iPTH: intact parathyroid hormone

Kt/V: Dialysis adequacy

MET: Metabolic rate

MVPA: Moderate to vigorous physical activity

PA: Physical activity

PUCPR: Pontifícia Universidade Católica do Paraná

RCT: Randomized controlled trial

SBP: Systolic blood pressure

Declarations

Ethics approval and consent to participate:

The HDFIT trial is was performed under a protocol approved by Pontifícia Universidade Católica do Paraná Ethics Review Board (Central tracking #: 54926916.7.1001.0020; Approval #: 1.538.784). All participants had provided written informed consent prior to participation in any study activities.

Consent for publication:

Not applicable.

Availability of data and materials:

The original source documents and electronic datasets, from the trial, as well as the coding from this analysis are not publicly available. The original trial documents, datasets, and coding are regulated and maintained by the EPICENTER ACRO.

Competing interests:

JWL, MH, MG are students at Pontifícia Universidade Católica do Paraná. JWL, HH, LAU, are employees of Fresenius Medical Care AG & Co. KGaA. MH, PK, JGR are employees of Renal Research Institute, a wholly owned subsidiary of Fresenius Medical Care North America. PGB receives travel support from Fresenius Medical Care. CEPF, ALCN receive consulting fees and speaker honorarium from Fresenius Medical Care. CEPF receives lecture fees and travel support from Fresenius Medical Care, Alexion, Baxter, and Astra Zeneca, and is employed by Pontifícia Universidade Católica do Rio Grande do Sul. ABLB is an employee of Fresenius Medical Care Brazil. LAU, PK have share options/ownership in Fresenius Medical Care. PK receives author honorarium from Up-To-Date and is on the Editorial Board of Blood Purification and Kidney and Blood Pressure Research. RPF, TPM are employed by Pontifícia Universidade Católica do Paraná. RPF, CEPF, TPM, MEFC are recipients of scholarships from the Brazilian Council for Research (CNPq). MEFC is employee by Federal University of São Paulo, and receives research grants, consulting fees, and honoraria from Baxter Healthcare and Fresenius Medical Care. RPF is employed by Arbor Research Collaborative for Health, and receives research grants, consulting fees, and honoraria from Astra Zeneca, Novo Nordisc, Akebia, and Fresenius Medical Care. All other authors declare no relevant conflicts of interest.

Funding:

This trial was a multi-center investigator-initiated study, whereby the site investigators and principal investigator were not being monetary funded for the conduct of study activities. This project was supported by: 1) the study investigators, 2) the proponent institution Pontifícia Universidade Católica do Paraná, 3) the outpatient dialysis centers, and 4) Fresenius Medical Care. The steering committee was comprised of nephrologists representing site institutions and supporting affiliates.

Investigators were involved in the design of the protocol and performed medical oversight and the coordination of data collection during the trial. The principal investigator provided medical oversight of the conduct of the trial at all sites under the guidance of the steering committee and coordinated the trial management.

The proponent institution Pontifícia Universidade Católica do Paraná supported the trial with infrastructure for study management through use of the university's ACRO, hosting of the REDCap

electronic case report form on the university's server, and use of the university's central Ethics Review Board and Research Council.

The outpatient dialysis centers permitted clinical research at the clinics and supported the trial with their clinical staff who performed data collection and the conduct of study procedures under the oversight of the site investigators and local trial leadership.

Fresenius Medical Care provided the sites with the infrastructure for the conduct of the trial including HDF machines, dialysis supplies for study participants, body composition monitor machines in clinics without them. Also, they provided some staff for site monitoring. Fresenius Medical Care provided a monetary award to PUCPR's ACRO (EPICENTER) that performed the central management, data acquisition, and monitoring. Fresenius Medical Care and the subsidiary company Renal Research Institute provided support from statistical experts to assist in the analysis of trial data under the oversight of the steering committee. Fresenius Medical Care has supported three investigator meetings, as well as three steering committee meetings. The leadership of Fresenius Medical Care reviewed and approved the protocol prior to commencement.

The steering committee members who represent supporting institutions reviewed and approved the research design, protocol, addendums and changes to the protocol, analyses, and this publication of study data, as well as provided oversight of the trial conduct and safety.

Authors' contributions:

Trial procedures were performed under the oversight of the principal investigator (RPF) and site investigators (Supplementary Appendix A). The design and conduct of the study was performed by: RPF, CEPF, ALCN, ABLB, TPM, PBG, MEFC and the HDFIT investigators and research staff (Supplementary Appendix A) and EPICENTER ACRO and affiliated staff (Supplementary Appendix B). The data collection, analytical design, and analysis for this study was conducted by: RPF, TPM, JWL, PBG, MG, HH, MH, LAU, PK, JGR. The intellectual content, interpretation, drafting and revision of this manuscript was performed by all authors, the HDFIT investigators (Supplementary Appendix A) and steering committee (Supplementary Appendix C). The decision to submit this manuscript for publication was jointly made by all authors and parties. The manuscript was confirmed to be accurate and approved by all authors.

Acknowledgements

We would like to acknowledge and thank the site investigators, participating dialysis centers and staff conducting this trial (Supplementary Appendix A); the EPICENTER ACRO staff and affiliates managing the trial (Supplementary Appendix B); and the external advisory committee members Bernard Canaud, MD, PhD, Cristina Marelli, MD, and Rodrigo S. Reis, PhD, MSc.

References

1. *Physical Activity Guidelines Advisory Committee report, 2008. To the Secretary of Health and Human Services. Part A: executive summary. Nutr Rev* 2009, 67(2):114–120.
2. Tudor-Locke C, Craig CL, Aoyagi Y, Bell RC, Croteau KA, De Bourdeaudhuij I, Ewald B, Gardner AW, Hatano Y, Lutes LD *et al: How many steps/day are enough? For older adults and special populations. Int J Behav Nutr Phys Act* 2011, 8:80.
3. Lopes AA, Lantz B, Morgenstern H, Wang M, Bieber BA, Gillespie BW, Li Y, Painter P, Jacobson SH, Rayner HC *et al: Associations of self-reported physical activity types and levels with quality of life, depression symptoms, and mortality in hemodialysis patients: the DOPPS. Clin J Am Soc Nephrol* 2014, 9(10):1702–1712.
4. Morishita S, Tsubaki A, Shirai N: *Physical function was related to mortality in patients with chronic kidney disease and dialysis. Hemodial Int* 2017.
5. Tudor-Locke C, Washington TL, Hart TL: *Expected values for steps/day in special populations. Prev Med* 2009, 49(1):3–11.
6. Han M, Williams S, Mendoza M, Ye X, Zhang H, Calice-Silva V, Thijssen S, Kotanko P, Meyring-Wosten A: *Quantifying Physical Activity Levels and Sleep in Hemodialysis Patients Using a Commercially Available Activity Tracker. Blood Purif* 2016, 41(1–3):194–204.
7. Williams S, Han M, Ye X, Zhang H, Meyring-Wosten A, Bonner M, Young C, Thijssen S, Marsh D, Kotanko P: *Physical Activity and Sleep Patterns in Hemodialysis Patients in a Suburban Environment. Blood Purif* 2017, 43(1–3):235–243.
8. Rosa CS, Bueno DR, Souza GD, Gobbo LA, Freitas IF, Jr., Sakkas GK, Monteiro HL: *Factors associated with leisure-time physical activity among patients undergoing hemodialysis. BMC Nephrol* 2015, 16:192.
9. Johansen KL, Chertow GM, Ng AV, Mulligan K, Carey S, Schoenfeld PY, Kent-Braun JA: *Physical activity levels in patients on hemodialysis and healthy sedentary controls. Kidney Int* 2000, 57(6):2564–2570.
10. Afsar B: *The relationship between intact parathyroid hormone levels and daily physical activity in hemodialysis patients. Int J Artif Organs* 2014, 37(5):350–357.
11. Zamojska S, Szklarek M, Niewodniczy M, Nowicki M: *Correlates of habitual physical activity in chronic haemodialysis patients. Nephrol Dial Transplant* 2006, 21(5):1323–1327.
12. van Sandwijk MS, Al Arashi D, van de Hare FM, van der Torren JMR, Kersten MJ, Bijlsma JA, Ten Berge IJM, Bemelman FJ: *Fatigue, anxiety, depression and quality of life in kidney transplant recipients, haemodialysis patients, patients with a haematological malignancy and healthy controls. Nephrol Dial Transplant* 2018.

13. Alavi NM, Aliakbarzadeh Z, Sharifi K: *Depression, anxiety, activities of daily living, and quality of life scores in patients undergoing renal replacement therapies. Transplant Proc* 2009, 41(9):3693–3696.
14. Kutner NG, Zhang R, Allman RM, Bowling CB: *Correlates of ADL difficulty in a large hemodialysis cohort. Hemodial Int* 2014, 18(1):70–77.
15. Han M, Ye X, Preciado P, Williams S, Campos I, Bonner M, Young C, Marsh D, Larkin JW, Usvyat LA et al: *Relationships between Neighborhood Walkability and Objectively Measured Physical Activity Levels in Hemodialysis Patients. Blood Purif* 2018, 45(1–3):236–244.
16. Flythe JE, Hilliard T, Castillo G, Ikeler K, Orazi J, Abdel-Rahman E, Pai AB, Rivara MB, St Peter WL, Weisbord SD et al: *Symptom Prioritization among Adults Receiving In-Center Hemodialysis: A Mixed Methods Study. Clin J Am Soc Nephrol* 2018, 13(5):735–745.
17. Bossola M, Di Stasio E, Marzetti E, De Lorenzis K, Pepe G, Vulpio C: *Fatigue is associated with high prevalence and severity of physical and emotional symptoms in patients on chronic hemodialysis. Int Urol Nephrol* 2018, 50(7):1341–1346.
18. Katayama A, Miyatake N, Nishi H, Ujike K, Hashimoto H, Kurato R, Koumoto K: *Relationship between Changes in Physical Activity and Changes in Health-related Quality of Life in Patients on Chronic Hemodialysis with 1-Year Follow-up. Acta Med Okayama* 2016, 70(5):353–361.
19. Gomes EP, Reboredo MM, Carvalho EV, Teixeira DR, Carvalho LF, Filho GF, de Oliveira JC, Sanders-Pinheiro H, Chebli JM, de Paula RB et al: *Physical Activity in Hemodialysis Patients Measured by Triaxial Accelerometer. Biomed Res Int* 2015, 2015:645645.
20. Carvalho EV, Reboredo MM, Gomes EP, Teixeira DR, Roberti NC, Mendes JO, Oliveira JC, Sanders-Pinheiro H, Pinheiro BV: *Physical activity in daily life assessed by an accelerometer in kidney transplant recipients and hemodialysis patients. Transplant Proc* 2014, 46(6):1713–1717.
21. Shibata S, Tsutou A, Shiotani H: *Relation between sleep quality and daily physical activity in hemodialysis outpatients. Kobe J Med Sci* 2014, 59(5):E161–166.
22. Matsuzawa R, Matsunaga A, Kutsuna T, Ishii A, Abe Y, Yoneki K, Harada M, Ishibashi M, Takeuchi Y, Yoshida A et al: *Association of habitual physical activity measured by an accelerometer with high-density lipoprotein cholesterol levels in maintenance hemodialysis patients. ScientificWorldJournal* 2013, 2013:780783.
23. Avesani CM, Trolonge S, Deleaval P, Baria F, Mafra D, Faxen-Irving G, Chauveau P, Teta D, Kamimura MA, Cuppari L et al: *Physical activity and energy expenditure in haemodialysis patients: an international survey. Nephrol Dial Transplant* 2012, 27(6):2430–2434.
24. Shimoda T, Matsuzawa R, Yoneki K, Harada M, Watanabe T, Matsumoto M, Yoshida A, Takeuchi Y, Matsunaga A: *Changes in physical activity and risk of all-cause mortality in patients on maintenance*

hemodialysis: a retrospective cohort study. BMC Nephrol 2017, 18(1):154.

25.Cupisti A, Capitanini A, Betti G, D'Alessandro C, Barsotti G: *Assessment of habitual physical activity and energy expenditure in dialysis patients and relationships to nutritional parameters. Clin Nephrol* 2011, 75(3):218–225.

26.Oishi D, Koitabashi K, Hiraki K, Imai N, Sakurada T, Konno Y, Shibagaki Y, Yasuda T, Kimura K: *Physical activity is associated with serum albumin in peritoneal dialysis patients. Adv Perit Dial* 2012, 28:148–152.

27.Masuda R, Imamura H, Mizuuchi K, Miyahara K, Kumagai H, Hirakata H: *Physical activity, high-density lipoprotein cholesterol subfractions and lecithin:cholesterol acyltransferase in dialysis patients. Nephron Clin Pract* 2009, 111(4):c253–259.

28.Pecoits-Filho R: *Impact of HemoDiaFiltration on Physical Activity and Self-Reported Outcomes (HDFIT). ClinicalTrials.gov Registry* 2016, <https://clinicaltrials.gov/ct2/show/NCT02787161> (Accessed 29 Sep 2019).

29.Pecoits-Filho R, Larkin JW, Poli-de-Figueiredo CE, Cuvello Neto AL, Barra AB, Canhada S, de Campos LG, Woehl J, Gonçalves PB, Han H *et al*: *Design and methodology of the impact of HemoDiaFiltration on physical activity and self-reported outcomes: a randomized controlled trial (HDFIT trial) in Brazil. BMC Nephrology* 2019, 20(1):98.

30.Plasqui G, Westerterp KR: *Physical activity assessment with accelerometers: an evaluation against doubly labeled water. Obesity (Silver Spring)* 2007, 15(10):2371–2379.

31.Yang CC, Hsu YL: *A review of accelerometry-based wearable motion detectors for physical activity monitoring. Sensors (Basel)* 2010, 10(8):7772–7788.

32.Evenson KR, Buchner DM, Morland KB: *Objective measurement of physical activity and sedentary behavior among US adults aged 60 years or older. Prev Chronic Dis* 2012, 9:E26.

33.O'Neill B, McDonough SM, Wilson JJ, Bradbury I, Hayes K, Kirk A, Kent L, Cosgrove D, Bradley JM, Tully MA: *Comparing accelerometer, pedometer and a questionnaire for measuring physical activity in bronchiectasis: a validity and feasibility study? Respir Res* 2017, 18(1):16.

34.Daugirdas JT: *Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol* 1993, 4(5):1205–1213.

35.Choi L, Liu Z, Matthews CE, Buchowski MS: *Validation of accelerometer wear and nonwear time classification algorithm. Med Sci Sports Exerc* 2011, 43(2):357–364.

36.Migueles JH, Cadenas-Sanchez C, Ekelund U, Delisle Nystrom C, Mora-Gonzalez J, Lof M, Labayen I, Ruiz JR, Ortega FB: *Accelerometer Data Collection and Processing Criteria to Assess Physical Activity and Other Outcomes: A Systematic Review and Practical Considerations. Sports Med* 2017, 47(9):1821–1845.

- 37.Sasaki JE, John D, Freedson PS: *Validation and comparison of ActiGraph activity monitors. J Sci Med Sport* 2011, *14*(5):411–416.
- 38.Freedson PS, Melanson E, Sirard J: *Calibration of the Computer Science and Applications, Inc. accelerometer. Med Sci Sports Exerc* 1998, *30*(5):777–781.
- 39.*Global Strategy on Diet, Physical Activity and Health: Physical Activity and Adults. World Health Organization* 2018, http://www.who.int/dietphysicalactivity/factsheet_adults/en/((Accessed 07 Nov 2018)).
- 40.Bleyer AJ, Hartman J, Brannon PC, Reeves-Daniel A, Satko SG, Russell G: *Characteristics of sudden death in hemodialysis patients. Kidney Int* 2006, *69*(12):2268–2273.
- 41.Lertdumrongluk P, Streja E, Rhee CM, Sim JJ, Gillen D, Kovesdy CP, Kalantar-Zadeh K: *Changes in pulse pressure during hemodialysis treatment and survival in maintenance dialysis patients. Clin J Am Soc Nephrol* 2015, *10*(7):1179–1191.
- 42.Piercy KL, Troiano RP: *Physical Activity Guidelines for Americans From the US Department of Health and Human Services. Circ Cardiovasc Qual Outcomes* 2018, *11*(11):e005263.
- 43.Parker K: *Intradialytic Exercise is Medicine for Hemodialysis Patients. Curr Sports Med Rep* 2016, *15*(4):269–275.
- 44.Kraus WE, Janz KF, Powell KE, Campbell WW, Jakicic JM, Troiano RP, Sprow K, Torres A, Piercy KL, Physical Activity Guidelines Advisory C: *Daily Step Counts for Measuring Physical Activity Exposure and Its Relation to Health. Med Sci Sports Exerc* 2019, *51*(6):1206–1212.
- 45.Lee IM, Shiroma EJ, Kamada M, Bassett DR, Matthews CE, Buring JE: *Association of Step Volume and Intensity With All-Cause Mortality in Older Women. JAMA Intern Med* 2019.
- 46.Dwyer T, Pezic A, Sun C, Cochrane J, Venn A, Srikanth V, Jones G, Shook RP, Sui X, Ortaglia A *et al*: *Objectively Measured Daily Steps and Subsequent Long Term All-Cause Mortality: The Tasped Prospective Cohort Study. PLoS One* 2015, *10*(11):e0141274.
- 47.Yamamoto N, Miyazaki H, Shimada M, Nakagawa N, Sawada SS, Nishimuta M, Kimura Y, Kawakami R, Nagayama H, Asai H *et al*: *Daily step count and all-cause mortality in a sample of Japanese elderly people: a cohort study. BMC Public Health* 2018, *18*(1):540.
- 48.Jefferis BJ, Parsons TJ, Sartini C, Ash S, Lennon LT, Papacosta O, Morris RW, Wannamethee SG, Lee IM, Whincup PH: *Objectively measured physical activity, sedentary behaviour and all-cause mortality in older men: does volume of activity matter more than pattern of accumulation? Br J Sports Med* 2018.
- 49.Cooke AB, Ta V, Iqbal S, Gomez YH, Mavrakanas T, Barre P, Vasilevsky M, Rahme E, Daskalopoulou SS: *The Impact of Intradialytic Pedaling Exercise on Arterial Stiffness: A Pilot Randomized Controlled Trial in*

a Hemodialysis Population. Am J Hypertens 2018, 31(4):458–466.

Tables

Table 1: Patient Characteristics

Parameter	Category	Total N	Mean ($\pm$ SD) or N and %
Age (years)		195	52.98 ($\pm$ 15.08)
Male (%)		195	139 (71)
Race	<i>White (%)</i>	195	115 (59)
	<i>Other (%)</i>		80 (41)
Comorbidities	<i>Diabetes (%)</i>	195	68 (35)
	<i>Coronary artery disease (%)</i>		33 (17)
	<i>Congestive heart failure (%)</i>		15 (8)
Dialysis access type	<i>Arteriovenous fistula (%)</i>	195	164 (84)
	<i>Arteriovenous graft (%)</i>		9 (5)
	<i>Permanent catheter (%)</i>		22 (11)
Etiology of CKD/ESKD	<i>Diabetic nephropathy (%)</i>	195	56 (29)
	<i>Hypertensive nephrosclerosis (%)</i>		51 (26)
	<i>Chronic glomerulonephritis (%)</i>		32 (16)
	<i>Interstitial nephritis (%)</i>		7 (4)
	<i>Chronic pyelonephritis (%)</i>		7 (4)
	<i>Polycystic Kidney Disease (%)</i>		11 (6)
	<i>Lupus Nephritis (%)</i>		5 (3)
	<i>Other (%)</i>		11 (6)
Family income level	<i>Unknown (%)</i>		15 (8)
	<i>Above 10 minimum wages (%)</i>	195	17 (9)
	<i>4 to 10 minimum wages (%)</i>		54 (28)
	<i>2 to 4 minimum wages (%)</i>		88 (45)
Education level	<i>Less than 2 minimum wages (%)</i>		36 (18)
	<i>Complete university (%)</i>	195	39 (20)
	<i>Complete high school (%)</i>		70 (36)
	<i>Complete elementary (%)</i>		53 (27)
Distance from home to clinic	<i>Incomplete elementary (%)</i>		33 (17)
	<i>Greater than 25 Km (%)</i>	195	48 (25)

	<i>Between 13 and 25 Km (%)</i>		47 (24)
	<i>Between 7 and 13 Km (%)</i>		46 (24)
	<i>Less than 7 Km (%)</i>		52 (27)
	<i>Missing (%)</i>		2 (1)
Transportation type to clinic	<i>Family car (%)</i>	195	84 (43)
	<i>Public transportation (%)</i>		65 (33)
	<i>Ambulance (%)</i>		32 (16)
	<i>Taxi (%)</i>		9 (5)
	<i>Walking (%)</i>		5 (3)
Height (cm)		195	168.13 (± 8.42)
Estimated dry weight (Kg)		194	75.25 (± 15.92)
Pre-dialysis weight (kg)		194	77.78 (± 15.98)
Post-dialysis weight (kg)		193	75.51 (± 15.79)
Pre-dialysis SBP (mmHg)		193	153.19 (± 23.7)
Pre-dialysis DBP (mmHg)		193	80.93 (± 13.43)
Pre-dialysis pulse (beats per minute)		194	75.58 (± 12.61)
Post-dialysis SBP (mmHg)		192	148.14 (± 23.01)
Post-dialysis DBP (mmHg)		190	77.44 (± 13.37)
Post-dialysis pulse (beats per minute)		189	74.39 (± 11.93)
Laboratories	<i>Pre-HD BUN (mg/dL)</i>	189	58.2 (13.1)
	<i>Post-HD BUN (mg/dL)</i>	195	17.1 (7.7)
	<i>Kt/V</i>	194	1.5 (0.4)
	<i>Albumin (g/dL)</i>	192	4.0 (0.4)
	<i>Potassium (mEq/L)</i>	195	5.2 (0.8)
	<i>Calcium (mg/dL)</i>	175	9.0 (0.7)
	<i>Phosphate (mg/dL)</i>	195	5.3 (1.4)
	<i>Intact parathyroid hormone (pg/mL)</i>	190	350.5 (290.0)
	<i>Hemoglobin (g/dL)</i>	193	11.1 (1.6)

Descriptive statistics are presented by parameter and category as applicable. The number of patients with valid data for each parameter are detailed in the third column (Total N); missing category data is detailed as applicable. The descriptive statistics in the fourth

column are presented as the mean value $\pm$ standard deviation (SD) for continuous variables or as the patient number (N) and percent (%) for categorical variables.

Table 2: Average Physical Activity (PA) Levels Per 24 Hours Overall and on HD Days, the First Non-HD Days and Second Non-HD Day

PA Measure	Overall ($\pm$ SD) <i>Per 24 Hrs</i>	HD Day ($\pm$ SD) <i>0-to-$\leq$24 Hrs after Start HD</i>	1 st Non-HD Day ($\pm$ SD) <i>>24-to-$\leq$48 Hrs after Start HD</i>	P-Value vs HD Day	2 nd Non-HD Day ($\pm$ SD) <i>>48-to-$\leq$72 Hrs after Start HD</i>	P-Value vs HD Day
Steps Count	4654 (3468)	3919 (2899)	5308 (3131)	<0.001	4926 (3413)	0.032
MET (kcal/kg/Hr)	1.08 (0.19)	1.09 (0.17)	1.09 (0.23)	0.797	1.07 (0.18)	0.027
MVPA Minutes	23.9 (32.6)	20.3 (27.0)	27.5 (31.3)	0.021	24.3 (28.3)	0.175
Light PA Minutes	361.2 (134.5)	294.5 (95.5)	402.5 (127.3)	<0.0001	386.7 (149.5)	<0.0001
Sedentary Time Minutes	488.0 (148.0)	523.2 (118.2)	453.4 (136.3)	<0.0001	487.3 (176.2)	0.026

Table 3: Average Physical Activity (PA) Levels Per Predefined Granular Slice Period on HD Days, the First Non-HD Days and Second Non-HD Day

Step Counts Per Predefined Granular Slice Period

Slice Period during/after HD or Concurrent Time	HD Day ($\pm$ SD)	1 st Non-HD Day ($\pm$ SD)	2 nd Non-HD Day ($\pm$ SD)
	<i>0-to-$\leq$24 Hrs after Start HD</i>	<i>>24-to-$\leq$48 Hrs after Start HD</i>	<i>>48-to-$\leq$72 Hrs after Start HD</i>
HD Period	97 (225)	1405*** (1067)	1225*** (1468)
0.0- $\leq$ 0.5 Hr Post-HD	261 (267)	180** (179)	137*** (177)
>0.5- $\leq$ 1.0 Hr Post-HD	282 (224)	203** (299)	147*** (211)
>1.0- $\leq$ 1.5 Hr Post-HD	243 (200)	164*** (183)	173* (323)
>1.5- $\leq$ 2.0 Hr Post-HD	179 (181)	142* (149)	148 (218)
>2.0- $\leq$ 6.5 Hr Post-HD	788 (772)	941 (925)	844 (926)
>6.5- $\leq$ 11.0 Hr Post-HD	608 (729)	718 (926)	704 (1058)
>11.0- $\leq$ 15.5 Hr Post-HD	964 (1668)	874 (1343)	1014 (1749)
>15.5- $\leq$ 20.0 Hr Post-HD	1257 (1352)	1327 (950)	1384 (1082)

MET Rate Per Predefined Granular Slice Period

Slice Period during/after HD or Concurrent Time	HD Day ($\pm$ SD)	1 st Non-HD Day ($\pm$ SD)	2 nd Non-HD Day ($\pm$ SD)
	<i>0-to-$\leq$24 Hrs after Start HD</i>	<i>>24-to-$\leq$48 Hrs after Start HD</i>	<i>>48-to-$\leq$72 Hrs after Start HD</i>
HD Period	1.0 (0.03)	1.1*** (0.2)	1.1*** (0.2)
0.0- $\leq$ 0.5 Hr Post-HD	1.1 (0.3)	1.1 (0.3)	1.0*** (0.1)
>0.5- $\leq$ 1.0 Hr Post-HD	1.1 (0.2)	1.1 (0.4)	1.0*** (0.2)
>1.0- $\leq$ 1.5 Hr Post-HD	1.1 (0.2)	1.1 (0.2)	1.1 (0.3)
>1.5- $\leq$ 2.0 Hr Post-HD	1.1 (0.2)	1.1 (0.2)	1.1 (0.2)
>2.0- $\leq$ 6.5 Hr Post-HD	1.1 (0.1)	1.1 (0.3)	1.0 (0.1)
>6.5- $\leq$ 11.0 Hr Post-HD	1.1 (0.2)	1.1 (0.2)	1.1 (0.2)
>11.0- $\leq$ 15.5 Hr Post-HD	1.1 (0.2)	1.1 (0.2)	1.1 (0.3)
>15.5- $\leq$ 20.0 Hr Post-HD	1.1 (0.1)	1.1 (0.1)	1.1 (0.1)

Minutes of MVPA Per Predefined Granular Slice Period

Slice Period during/after HD or Concurrent Time	HD Day ($\pm$ SD)	1 st Non-HD Day ($\pm$ SD)	2 nd Non-HD Day ($\pm$ SD)
	<i>0-to-$\leq$24 Hrs after Start HD</i>	<i>>24-to-$\leq$48 Hrs after Start HD</i>	<i>>48-to-$\leq$72 Hrs after Start HD</i>

HD Period	0.3 (10.8)	7.5*** (1.6)	5.8*** (12.4)
0.0-≤0.5 Hr Post-HD	1.3 (1.8)	0.9 (2.4)	0.6** (1.7)
>0.5-≤1.0 Hr Post-HD	1.2 (2.6)	1.1 (2.0)	0.5** (2.1)
>1.0-≤1.5 Hr Post-HD	0.9 (1.7)	0.8 (1.6)	0.8 (2.9)
>1.5-≤2.0 Hr Post-HD	0.7 (1.5)	0.7 (1.4)	0.6 (1.7)
>2.0-≤6.5 Hr Post-HD	3.6 (7.4)	4.3 (6.1)	4.3 (9.2)
>6.5-≤11.0 Hr Post-HD	3.0 (7.0)	3.7 (4.5)	3.4 (7.0)
>11.0-≤15.5 Hr Post-HD	6.6 (13.7)	5.6 (15.4)	6.1 (13.7)
>15.5-≤20.0 Hr Post-HD	7.1 (8.3)	6.4 (12.0)	6.6 (8.8)

Minutes of Light PA Per Predefined Granular Slice Period

Slice Period during/after HD or Concurrent Time	HD Day (±SD)	1 st Non-HD Day (±SD)	2 nd Non-HD Day (±SD)
	<i>0-to-≤24 Hrs after Start HD</i>	<i>>24-to-≤48 Hrs after Start HD</i>	<i>>48-to-≤72 Hrs after Start HD</i>
HD Period	13.3 (18.0)	101.4*** (41.6)	95.7*** (50.6)
0.0-≤0.5 Hr Post-HD	13.6 (5.5)	13.9 (7.3)	13.1 (8.6)
>0.5-≤1.0 Hr Post-HD	17.3 (6.1)	13.5*** (7.1)	13.5*** (8.7)
>1.0-≤1.5 Hr Post-HD	16.1 (6.9)	12.9*** (6.6)	12.9*** (9.2)
>1.5-≤2.0 Hr Post-HD	13.4 (6.5)	12.5 (6.9)	13.0 (9.9)
>2.0-≤6.5 Hr Post-HD	72.5 (43.6)	86.4** (53.7)	82.5 (54.3)
>6.5-≤11.0 Hr Post-HD	56.7 (45.2)	60.8 (47.8)	61.9 (49.2)
>11.0-≤15.5 Hr Post-HD	56.4 (50.7)	54.4 (48.0)	63.1 (57.2)
>15.5-≤20.0 Hr Post-HD	89.6 (56.9)	92.1 (42.6)	94.7 (53.3)

Minutes of Sedentary Time Per Predefined Granular Slice Period

Slice Period during/after HD or Concurrent Time	HD Day (±SD)	1 st Non-HD Day (±SD)	2 nd Non-HD Day (±SD)
	<i>0-to-≤24 Hrs after Start HD</i>	<i>>24-to-≤48 Hrs after Start HD</i>	<i>>48-to-≤72 Hrs after Start HD</i>
HD Period	178.0 (57.2)	98.8*** (49.6)	113.2*** (61.4)
0.0-≤0.5 Hr Post-HD	14.6 (6.0)	14.6 (7.7)	15.9 (9.1)
>0.5-≤1.0 Hr Post-HD	11.3 (6.0)	14.8*** (7.7)	15.6*** (9.0)
>1.0-≤1.5 Hr Post-HD	12.7 (7.3)	15.6*** (7.1)	16.0*** (9.7)
>1.5-≤2.0 Hr Post-HD	14.8 (6.7)	15.5 (7.2)	15.7 (10.2)

>2.0-≤6.5 Hr Post-HD	125.3 (59.4)	118.3 (56.5)	128.9 (64.1)
>6.5-≤11.0 Hr Post-HD	92.6 (66.1)	91.2 (59.4)	101.9 (76.4)
>11.0-≤15.5 Hr Post-HD	64.9 (47.4)	61.9 (45.2)	75.6 (65.7)
>15.5-≤20.0 Hr Post-HD	82.6 (52.7)	80.9 (43.5)	90.3 (63.9)
***, p<0.001; **, p<0.01; *, p<0.05			

Table 4: Average Physical Activity (PA) Levels on HD Days Per 24 Hours by Dialysis Shift

HD Shift	Steps Per 24 Hrs on HD Days (±SD)	P-Value vs HD before 1500 Hrs	Minutes of MVPA Per 24 Hrs on HD Days (±SD)	P-Value vs HD before 1500 Hrs
HD start before 1500 Hrs	3390 (2313)	Reference	15.6 (20.0)	Reference
HD start after 1500 Hrs	5547 (4613)	<0.0001	34.2 (46.2)	<0.0001

Table 5: Average Physical Activity (PA) Levels on HD Days Per Predefined Granular Slice Period by Dialysis Shift

Step Counts Per Predefined Granular Slice Period			
Slice Period during/after HD	HD Start before 1500 Hrs (±SD)	HD Start after 1500 Hrs (±SD)	P-Value vs before 1500 Hrs
HD Period	93 (244)	124 (254)	0.447
0.0-≤0.5 Hr Post-HD	229 (231)	345 (347)	0.011
>0.5-≤1.0 Hr Post-HD	288 (231)	247 (191)	0.270
>1.0-≤1.5 Hr Post-HD	254 (194)	202 (210)	0.119
>1.5-≤2.0 Hr Post-HD	194 (179)	126 (176)	0.025
>2.0-≤6.5 Hr Post-HD	949 (798)	269 (319)	<0.0001
>6.5-≤11.0 Hr Post-HD	570 (660)	767 (968)	0.192
>11.0-≤15.5 Hr Post-HD	344 (483)	2085 (2320)	<0.0001
>15.5-≤20.0 Hr Post-HD	968 (1130)	1839 (1563)	<0.0001
MVPA Per Predefined Granular Slice Period			
Slice Period during/after HD	HD Start before 1500 Hrs (±SD)	HD Start after 1500 Hrs (±SD)	P-Value vs before 1500 Hrs
HD Period	0.3 (1.7)	0.5 (1.7)	0.605
0.0-≤0.5 Hr Post-HD	1.0 (2.0)	2.2 (3.2)	0.005
>0.5-≤1.0 Hr Post-HD	1.2 (2.0)	1.1 (1.7)	0.747
>1.0-≤1.5 Hr Post-HD	0.9 (1.6)	1.0 (1.6)	0.773
>1.5-≤2.0 Hr Post-HD	0.7 (1.4)	0.6 (1.3)	0.4841
>2.0-≤6.5 Hr Post-HD	4.3 (6.7)	1.2 (2.0)	<0.0001
>6.5-≤11.0 Hr Post-HD	2.7 (4.0)	4.5 (6.2)	0.059

>11.0-≤15.5 Hr Post-HD	2.2 (4.6)	14.2 (23.0)	<0.0001
>15.5-≤20.0 Hr Post-HD	5.1 (8.6)	11.0 (16.2)	0.004

Table 6: Average Physical Activity (PA) Levels on HD Days Per 24 Hours by Dialysis Day of the Week

HD Session of Week	Steps Count Per 24 Hrs (±SD)	P-Value vs HD 1	Minutes of MVPA Per 24 Hrs (±SD)	P-Value vs HD 1
HD 1 (Monday/Tuesday)	3981 (3096)	Reference	21.0 (27.9)	Reference
HD 2 (Wednesday/Thursday)	3976 (3289)	0.987	20.5 (30.5)	0.872
HD 3 (Friday/Saturday)	3820 (3270)	0.637	19.1 (32.5)	0.560

Table 7: Average Physical Activity (PA) Levels on HD Days Per Predefined Granular Slice Period by Dialysis Day of the Week

Step Counts Per Predefined Granular Slice Period					
Slice Period during/after HD	HD 1 (±SD)	HD 2 (±SD)	P-Value vs HD 1	HD 3 (±SD)	P-Value vs HD 1
HD Period	70 (142)	133 (550)	0.155	83 (183)	0.460
0.0-≤0.5 Hr Post-HD	255 (300)	273 (311)	0.586	265 (337)	0.766
>0.5-≤1.0 Hr Post-HD	272 (294)	287 (277)	0.633	293 (336)	0.945
>1.0-≤1.5 Hr Post-HD	243 (246)	252 (252)	0.742	247 (256)	0.885
>1.5-≤2.0 Hr Post-HD	205 (247)	191 (278)	0.629	170 (203)	0.170
>2.0-≤6.5 Hr Post-HD	808 (814)	816 (1002)	0.936	858 (1137)	0.655
>6.5-≤11.0 Hr Post-HD	568 (758)	675 (1087)	0.363	645 (774)	0.426
>11.0-≤15.5 Hr Post-HD	1132 (2038)	1081 (2078)	0.851	1047 (1971)	0.752
>15.5-≤20.0 Hr Post-HD	1441 (1588)	1337 (1585)	0.598	1253 (1649)	0.355
MVPA Per Predefined Granular Slice Period					
Slice Period during/after HD	HD 1 (±SD)	HD 2 (±SD)	P-Value vs HD 1	HD 3 (±SD)	P-Value vs HD 1
HD Period	0.4 (1.2)	0.5 (4.3)	0.656	0.2 (0.9)	0.059
0.0-≤0.5 Hr Post-HD	1.4 (2.8)	1.3 (2.9)	0.665	1.3 (2.9)	0.642
>0.5-≤1.0 Hr Post-HD	1.2 (2.5)	1.2 (2.5)	0.551	1.1 (3.1)	0.762
>1.0-≤1.5 Hr Post-HD	1.0 (2.3)	0.9 (1.8)	0.570	0.9 (2.0)	0.520
>1.5-≤2.0 Hr Post-HD	0.9 (2.2)	0.8 (2.3)	0.840	0.5 (1.3)	0.042
>2.0-≤6.5 Hr Post-HD	3.5 (6.4)	3.4 (7.9)	0.970	4.4 (11.2)	0.336
>6.5-≤11.0 Hr Post-HD	2.9 (4.9)	2.9 (6.3)	0.944	3.4 (6.5)	0.501
>11.0-≤15.5 Hr Post-HD	7.5 (19.1)	7.5 (18.5)	0.998	7.2 (19.8)	0.905
>15.5-≤20.0 Hr Post-HD	8.1 (14.1)	8.2 (16.6)	0.947	6.2 (14.4)	0.275

Figures

Design for the Capture of Physical Activity Levels

Activity tracking over 7 days starting at the initiation of hemodialysis (HD), or concurrent/parallel times on non-HD days and the long interdialytic day

Figure 1

Schematic of the design for the export and analysis of physical activity levels in in reference to the timing of the start of HD, or concurrent/parallel times on non-HD days. Data was capture over 24 hours periods in 3 blocks. The blocks were sliced to periods to investigate granular profiles after HD.

Screening

Patients Consented = 199

Withdraw of Consent = 2

Enrollment

Patients Enrolled = 197

Enrolled in Error and Withdrawn = 2

Baseline Analysis Cohort

Patients Included in Analysis = 195

Figure 2

Participant Flow Diagram

Figure 3

Normalized rates for steps per hour with 95% confidence intervals in the prespecified periods 0-to-≤24 hours after the start of HD on HD days (solid gray columns), >24-to-≤48 hours after the start of HD on the first non-HD days (white with black dotted columns), and >48-to-≤72 hours after the start of HD on the second non-HD day (horizontal black striped columns). Times during and post-HD/concurrent periods are presented on the x axis and the rate of steps per hour is shown on the y-axis.

Figure 4

Normalized rates for minutes of MVPA per hour with 95% confidence intervals in the prespecified periods 0-to-≤24 hours after the start of HD on HD days (solid gray columns), >24-to-≤48 hours after the start of HD on the first non-HD days (white with black dotted columns), and >48-to-≤72 hours after the start of HD on the second non-HD day (horizontal black striped columns). Times during and post-HD/concurrent periods are presented on the x axis and the rate of MVPA per hour is shown on the y-axis.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [HDFITBLProfilesPASupplementalDocs29Sep2019.docx](#)
- [STROBEchecklist.docx](#)